hydroxyurea has been researched along with arsenic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, LC; Autero, M; Mustelin, T; Oetken, C; Ruutu, T; von Willebrand, M | 1 |
| Gottlieb, M; Mackow, MC; Neubert, TA | 1 |
| Newbold, PC | 1 |
| Carr, HS; Hjorth, R; Rosenkranz, HS | 1 |
| Burdon, RH; Cato, AC; McMahon, M; Slater, A | 1 |
| Lindelöf, B; Sigurgeirsson, B | 1 |
| Hara, S; Ishitsuka, K; Iwao, Y; Shirahashi, A; Shishime, M; Suzumiya, J; Takamatsu, Y; Takatsuka, Y; Tamura, K; Utsunomiya, A | 1 |
| Huang, Q | 1 |
| Ji, XM; Jia, JP; Li, LM; Meng, R; Yang, BF; Zhou, J | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
2 review(s) available for hydroxyurea and arsenic
| Article | Year |
|---|---|
Antimetabolites and psoriasis.
Topics: Adrenal Cortex Hormones; Animals; Antimetabolites; Arsenic; Humans; Hydroxyurea; Methotrexate; Mice; Neoplasms; Nucleic Acids; Protein Biosynthesis; Psoriasis; Time Factors; Ultraviolet Rays | 1972 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
9 other study(ies) available for hydroxyurea and arsenic
| Article | Year |
|---|---|
Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.
Topics: Aged; Animals; Arsenicals; Blood Platelets; Busulfan; Cell Line; Dithiothreitol; Gene Rearrangement; Granulocytes; Humans; Hydroxyurea; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Phosphates; Phosphoproteins; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases; Tyrosine | 1992 |
Crithidia luciliae: factors affecting the expression of 3'-nucleotidase/nuclease activity.
Topics: Adenosine; Animals; Arginine; Arsenic; Arsenites; Crithidia; Culture Media; Cycloheximide; Dactinomycin; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Hemin; Hydroxyurea; Molecular Weight; Nucleotidases; Purines; Sodium Compounds; Substrate Specificity; Tunicamycin | 1988 |
Studies with hydroxyurea. The biologic and metabolic properties of formamidoxime.
Topics: Amides; Arsenic; Ascitic Fluid; Azides; Chemical Phenomena; Chemistry, Physical; Chloramphenicol; DNA; DNA Nucleotidyltransferases; DNA, Bacterial; Drug Stability; Drug Synergism; Escherichia coli; Formamides; Hydroxyurea; Mutation; Oximes; Puromycin; Ribosomes; RNA, Bacterial; Tritium; Uracil | 1971 |
Hyperthermia and the heat-shock proteins of HeLa cells.
Topics: Amino Acids; Arsenic; Arsenites; Cytoplasm; DNA; Electrophoresis, Polyacrylamide Gel; Heat-Shock Proteins; HeLa Cells; Hot Temperature; Humans; Hydroxyurea; Protein Biosynthesis; Sodium Compounds; Subcellular Fractions; Sulfhydryl Reagents; Time Factors | 1982 |
PUVA and cancer: a case-control study.
Topics: Adult; Aged; Arsenic; Carcinoma, Squamous Cell; Case-Control Studies; Coal Tar; Combined Modality Therapy; Female; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; PUVA Therapy; Radiotherapy; Skin Neoplasms; Ultraviolet Therapy; X-Rays | 1993 |
Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Fever; Humans; Hydroxyurea; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Necrosis; Oxides; Pancytopenia; Remission Induction | 2004 |
Chronic myelogenous leukemia in accelerated phase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic | 2005 |
[The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Harringtonines; Hematocrit; Humans; Hydroxyurea; Male; Middle Aged; Oxides; Polycythemia Vera; Prognosis; Stroke | 2006 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |